The targeting of KIT and the JAK-STAT pathway have proven effective in the treatment of systemic mastocytosis and PMF with KIT inhibitors and JAK inhibitors, respectively [111,112], but are outside the scope of this review. Here, KIT is linked to mastocytosis.